Singapore: Cordlife makes US$880m bid for GCBC

Singapore’s Cordlife Group has made a US$7.50 per share bid for NYSE-listed Global Cord Blood Corporation (GCBC), China’s largest provider of cord blood storage and ancillary services. Under the proposal, Cordlife plans to issue 2.5 billion shares with a total value of S$1.2bn (US$880m), based on an issue price of S$0.50 per Cordlife share, in exchange…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »